Concerns the Galapagos-partnered JAK inhibitor would be held back by a testicular toxicity study have been calmed by positive FDA talks and a submission is due before the end of the year.
The US filing for rheumatoid arthritis (RA) of Gilead Sciences Inc. and Galapagos NV's closely watched filgotinib is now expected by the end of this year, allaying fears that the drug would be at a competitive disadvantage to AbbVie Inc.’s already-submitted rival JAK inhibitor upadacitinib.
Gilead has announced that it has held a pre-submission meeting with the US Food and Drug Administration to provide an...
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
